SUSMED,Inc.
Research SUSMED,Inc. (4263.T) on Bullrun: market cap JPY 6.36B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4263.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyJPY
- Market capJPY 6.36B
- Financial periodFY2025
Valuation Snapshot
latest market cap is JPY 6.36B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -17.77 | n/a | n/a | n/a |
| FY2024 | JPY 342.58M | -JPY 357.42M | -JPY 240.04M | 96.6% | -21.41 | JPY 4.85B | n/a | JPY 4.60B |
| FY2023 | JPY 530.65M | -JPY 50.75M | JPY 82.40M | 98.5% | -3.09 | JPY 5.05B | n/a | JPY 4.87B |
| FY2022 | JPY 316.87M | -JPY 233.48M | -JPY 177.90M | 96.7% | -15.9 | JPY 4.90B | n/a | JPY 4.85B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 6.36B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications and platform systems in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone-based therapeutic apps for diseases, such as insomnia, breast cancer, and kidney disease. It also develops and provides clinical trial systems with blockchain technology. In addition, the company offers medical data analysis and consulting services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SUSMED,Inc.'s market cap?
SUSMED,Inc.'s market capitalization is JPY 6.36B.
What does SUSMED,Inc. do?
SUSMED,Inc. develops and sells therapeutic applications and platform systems in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone-based therapeutic apps for diseases, such as insomnia, breast cancer, and kidney disease. It also develops and provides clinical trial systems with blockchain technology. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.